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 2 - MATERIAL AND METHODS 
 Subjects and assays 
  To perform this study we  groups: one comprising 36 individuals 
without clinical diagnosis of GS (14 with 6/6TA, 11 with 6/7TA, and 
11 with 7/7TA repeats); the other group consisting of 36 patients 
clinically diagnosed with GS. In both, bilirubin levels were 
determined and direct sequencing of the UGT1A1 gene was 
performed. Exclusion criteria for both groups has the presence of 
hematologic or hepatic disorder and been under medication. For 
each individual, after an overnight fasting, venous blood samples 
were collected in order to determine total and direct-reacting 
bilirubin and. Genomic DNA was isolated for molecular study of 
UGT1A1 gene promoter, followed PCR amplification as previously 
described5. In order to study the pathogenecity of the new 
mutations, sequences were analyzed in the Biosoftware Alamut. 
For statistical analysis, the Statistical Package for Social 
Sciences, version 17.0 was used. The variable TA repeat 
polymorphism was categorize in Normal (6/6), Heterozygous (6/7) 
and  Homozygous (7/7). To compare groups we use Kruskal-Wallis 
test. Significance was accepted at p<0.05.  
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4 – CONCLUSIONS 
 
Our study showed: 
1)  Homozygosity for the TA duplication is associated with GS.  
2) TA polymorphism is also responsible for the interindividual 
variation observed among individuals in general population. 
Statistical differences occur within genotype 6/6 and 6/7 
(p<0.0001) and is more pronounced between 6/6 and 7/7 genotype 
3) We found homozigous for the TA polymorphism, without further 
mutations in coding regions, that have normal ranges of serum 
bilirubin concentration. Probably other genetic  and non-genetic 
factors could contribute to the bilirubin variation in Portuguese 
population 
4) In the GS group with heterozygosity for the TA duplication, we 
found variants in 43% of the patients, and mutations in UGT1A1 
coding region are associated with more pronounced 
hiperbilirubinemia. This two observations emphasize the 
importance of complete UGT1A1 sequence analysis.  
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UGT1A1 gene variations in individuals with and without clinical diagnosis 
of Gilbert Syndrome 
 
1 – INTRODUCTION 
Bilirubin is a non-polar metabolite, results from catabolism of 
haemoglobin and is bound to glucuronic acid in the liver by the 
uridine diphosphate glucuronosyltransferase (UGT1A1). Molecular 
studies showed that the presence of two extra bases [A(TA)7TAA] in 
the promoter region of the UGT1A1 gene is responsible for the 
reduced UGT1A1 glucuronization activity and is the main cause of 
unconjugated hyperbilirubinemia observed in patients with Gilbert 
Syndrome (GS). However, individuals with normal bilirubin levels 
and no clinical symptoms of SG may also present this 
polymorphism in homozygosity 1,2,3. This polymorphism is not 
sufficient to explain the inter-individual variation and the presence 
of hiperbilirubinemia4. 
The aim of this work is to determine the presence of other mutations 
in the UGT1A1 gene, downstream of the TA duplication, and how 
they may contribute towards the inter-individual variation of serum 
bilirubin levels.  
3 - RESULTS 
Fig. 1. Partial sequence 
around the c.1423C>T 
mutation site, exon 5 of 
the UGT1A1 gene. (A) 
Normal sequence. (B) 
Heterozygous patient. 
Table 1. UGT1A1 TA polymorphism and other sequence 
variations of coding regions, in GS patients and in 
Controls. 
3 - DISCUSSION 
In the group without GS, TA polymorphism is also responsible for 
different bilirubin concentrations. In this group no mutations were 
detected in the 6/7 and 7/7 clusters, but in the 6/6 group two new 
mutations were found in heterozygosity. These mutations are not 
associated with increased bilirubin levels. However, they could be 
associated with GS in the presence of other UGT1A1 mutations. 
Most of the  patients clinically diagnosed with GS, were 
homozygous and only one as a normal number of repeats. 
Molecular analysis showed that one (3,6%) of the 7/7TA patients 
had another mutation in the UGT1A1 gene (c.674T>G).. Comparing 
In the 6/7TA group, one additional mutation was also found in 
three patients (43%), two of which had been previously described 
(c.674T>G; c.923G>A) and a new one (c.1423C>T; Fig. 1). As 
shown in Fig2B mutations in coding regions are associate  with 
increased serum bilirubin levels Additionally, 4 polymorphisms 
were found (c.864+89C>T; c.997-37T>C; c.997-82A>C; c.
997-87A>C) and are not associated with increased serum bilirubin 
levels. 
 
     Fig. 2. Differences between total bilirubin concentration (mg/dL) according to:  (A) 
Genotypes 6/6, 6/7 and 7/7 in individuals without GS; (B) between individuals without GS 
with genotype 7/7 and for the two GS patients groups (with homozygosity for [TA]7 alelle , 
and with one allele [TA]7 and the other with a mutation in coding region. 
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